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ABSTRACT
The aim of this study was to develop a microparticulate delivery system for acid-labile lansoprazole. The solvent evaporation method
was employed to prepare Eudragit® RS-100 microparticles (RS-microparticles). The effects of three parameters, including polymer concentration, drug concentration and homogenization rate, on microparticle performance were evaluated. The results revealed that the homogenization rate played an important role on the microparticle size. Increasing the polymer concentration and decreasing the drug concentration
enhanced the efficiency of drug encapsulation in RS-microparticles. The release of drug from RS-microparticles was governed by both
Fickian diffusion and polymer swelling mechanisms. The RS-microparticles were further enteric coated by hydroxypropyl methyl cellulose
phthalate (HPMCP) to improve the acid-resistance of lansoprazole.
Key words: microparticles, lansoprazole, solvent evaporation, spray drying

INTRODUCTION
For the last few decades, microparticles have played an
important role in drug delivery systems. Because microparticles have multiunits in their dosage form, they are more
uniformly distributed in the gastrointestinal tract and have
lower risk of dose dumping. These qualities account for more
consistent drug absorption and reduced variability among
subjects(1,2). In addition, polymeric microparticles have been
used to encapsulate acid-labile drugs and peptides (e.g., leuprolide) to prevent degradation in the gastrointestinal tract(3,4).
Compounds with a short biological half-life can be encapsulated inside microparticles to prolong sustained release(5,6).
The microparticles were also feasible to deliver drugs via
pulmonary inhalation route(7,8).
Lansoprazole acts as a proton pump inhibitor to treat
gastric ulcers and gastroesophageal diseases. Unfortunately, it
is not stable in gastric acidic condition, where protons attack its
sulfoxide structure and cause lansoprazole degradation(9,10).
The degradation of lansoprazole is not only pH-dependent
but also sensitive to light(11). Increase in storage temperature
from room temperature to 60°C accelerates lansoprazole
degradation and changes its color from light yellow-white
to dark brown-red(12). The stability of lansoprazole can be
* Author for correspondence. Tel: +886-2-23123456 ext 88396;
Fax: +886-2-23916126; E-mail: wjlin@ntu.edu.tw

improved by incorporation of svarious types of salts, such
as sodium carbonate, sodium bicarbonate, magnesium oxide,
magnesium hydroxide etc, so that it remains stable at 40°C
under 75% relative humidity for three months(9). The enteric
coating is a feasible approach to protect acid-labile drugs
from degradation in acidic environment. The enteric coating
of microparticles with Eudragit® S100 and hydroxypropyl
methyl cellulose (HPMC) has been demonstrated(2,13).
The enteric coating oral dosage form promises intact drug
absorption from the intestinal tract into gastric parietal cells
to activate drug into a sulfonamide derivative that irreversibly binds to the sulfhydryl group of H+/K+-ATPase to inhibit
gastric secretion. The pharmacokinetic studies of lansoprazole have been conducted in healthy volunteers via a crossover design(14), where each subject was orally administered
enteric coated granules in a hard gelatin capsule or received
lansoprazole intravenously. Similar pharmacokinetic results
were obtained from both oral and intravenous lansoprazoles .
Eudragit® RS-100 is a water insoluble material that
swells in water to produce interconnected channels for drug
release(15). Eudragit is widely used as a sustained-release
material to control drug release from different dosage
forms, for example, the microparticles for gentamicin, the
matrix type tablets for nicorandil, the osmotic tablets for
terbutaline, and the microparticles following compression
into a tablet for verapamil(16-19). Cellulose derivatives, e.g.,

439
Journal of Food and Drug Analysis, Vol. 20, No. 2, 2012

hypromellose acetate succinate and hydroxypropyl methyl
cellulose phthalate (HPMCP), as well as the copolymers of
methacrylic acid and its esters bearing free carboxyl groups,
e.g., Eudragit® L100-55, have been utilized as enteric coating
materials. Site-specific delivery of the drug to the small
intestine can be achieved via proper modification of the
succinoyl group content of hypromellose acetate succinate. It
has been shown that the succinoyl group content determines
drug solubility and dissolution at different pH conditions.
Fumie´ found that hypromellose acetate succinate with a 5%
succinoyl content starts to dissolve in the small intestine,
and the drug is immediately released(20). A pH-sensitive
nanoparticle system was developed by incorporating a negatively charged polymer, Eudragit L100-55, with a positively
charged polymer (e.g., chitosan). This system is beneficial
for the entrapment of hydrophilic polypeptide insulin without
affecting its conformation and activity(21). However, the free
carboxyl group of Eudragit® L100-55 is not suitable as an
enteric material for acid-labile lansoprazole.
This study was aimed to develop a microparticulate
delivery system with acid-resistance and sustained-release
properties for acid-labile lansoprazole. The solvent evaporation method was used to prepare Eudragit RS-microparticles.
The effects of three parameters including polymer concentration, drug concentration and homogenization rate on Eudragit
RS-microparticle performance were investigated. The
RS-microparticles were further coated by an enteric coating
material HPMCP by a spray drying method. The influence
of the enteric coating on the acid resistance of HPMCP-RSmicroparticles was evaluated.

MATERIALS AND METHODS
I. Materials
Lansoprazole was kindly shared by Syn-Tech Chem.
Pharm. Co., Ltd. (Tainan, Taiwan). Eudragit® RS-100 was
from Rohm Pharma. (Darmstaddt, Germany). HPMCP
PH-55, (h 40 cps), was from Shin Etsu Chemical Co., Ltd.
(Tokyo, Japan). Polyvinyl alcohol (PVA) and Tween 80
were from Acros Organics (NJ, USA). Sodium bicarbonate,
sodium hydroxide, talc and propylene glycol were from Wako
Pure Chemical Industries, Ltd. (Osaka, Japan). Pluronic F68
was from BASF (Ludwigshafen, Germany). Aerosil 200 was
from Evonik Rohm GmbH (Darmstadt, Germany). Methanol,
acetonitrile and dichloromethane were of HPLC grade from
Tedia Company Inc. (Fairfield, USA).
II. RS-microparticle Preparation
Ten batches of microparticles were prepared by solvent
evaporation method, which encompassed various polymer
concentration (4, 8, and 16%), drug concentration (0.8, 4,
and 8%), and homogenization rate (2000 and 7000 rpm) as
shown in Table 1. Eudragit RS-100 and lansoprazole were
dissolved in 5 mL dichloromethane and mixed well. The

Table 1. Three variables for RS-microparticle preparation.
Symbol*

Polymer conc.
(%)

Homogenization
(rpm)

Drug conc.
(%)

R47000-4

4

7000

4.0

R42000-4

4

2000

4.0

R87000-0.8

8

7000

0.8

R87000-4

8

7000

4.0

R87000-8

8

7000

8.0

R82000-0.8

8

2000

0.8

R82000-4

8

2000

4.0

R82000-8

8

2000

8.0

R167000-4

16

7000

4.0

R162000-4

16

2000

4.0

* “R” represents the RS-microparticles prepared by using Eudragit®
RS100. The first, second and third number represent the polymer
concentration, homogenization rate and drug concentration three
variables.

organic phase containing Eudragit RS-100 and lansoprazole was slowly added into 0.25% PVA aqueous solution
(pH 9.0), and homogenized for 30 min. The emulsion was
vacuumed by rotary evaporation for 1 h to remove dichloromethane, and then centrifuged at 4,500 rpm for 10 min.
The microparticles were collected and washed with distilled
water several times. Finally, the microparticles were freezedried and collected.
III. HPMCP-RS-Microparticle Preparation
The RS-microparticles were further coated by an
enteric coating material, HPMCP by spray drying method.
HPMCP (1 g) was dissolved in 50 mL 0.1 N NaHCO3
aqueous solution containing 0.5% Pluronic F68, 0.2 mL
propylene glycol, 0.5% Tween 80, 500 mg talc and 250 mg
Aerosil 200. The RS-microparticles 200 mg were dispersed
in HPMCP polymer solution in 50 mL 0.1 N NaHCO3
followed by spray drying (BUCHI B-290, Switzerland). The
spray drying condition was set as follows: inlet temperature 120°C, outlet temperature 69 ± 2°C, pump rate 12 mL/
min, aspirator 90%, and a compressed air flow rate of 400
L/h. Finally, the HPMCP enteric coated RS-microparticles
(HPMCP-RS-microparticles) were obtained. In order to
evaluate their acid resistance, 200 mg of microparticles
was suspended in a dialysis bag (cutoff MW 6,000-8,000)
containing 5 mL 0.1 N HCl which was then placed in a vial
containing 60 mL of the same release medium at 37°C for
1 h(22,23). After that, 0.6 mL 1 N NaOH was added into the
dialysis bag to neutralize the solution. The microparticles
were recovered by filtration and washed with deionized
water several times. The collected microparticles were
dissolved in 5 mL methanol/acetone (1:9; v/v), and the
amount of lansoprazole was measured by high performance
liquid chromatography (HPLC) at 285 nm.
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IV. HPLC Condition
Lansoprazole was assayed on an HPLC system equipped
with a reverse-phase column (Sphereclone ODS RP-18, 250
x 4 mm, 5 mm) and a UV spectrophotometer at a wavelength
of 285 nm (Shimadzu SPD-6AV). The mobile phase constituted of acetonitrile and phosphate buffer solution (pH 7.0)
in a ratio of 45 : 55 (v/v) was applied at a flow rate of 1.0
mL/min. The HPLC analytical method was validated before
sample analysis.
V. Characterization of Microparticles
The morphology of the microparticles was observed
under a scanning electron microscope (SEM, JEOL,
JSM-6300, Japan). The microparticles were placed on the
stage, coated with gold-palladium under argon atmosphere,
and observed with a SEM. The average particle size of the
microparticles was measured. The yield of RS-microparticles was calculated by dividing the recovered amount of
microparticles by the initial total weight of the polymer and
drug. The yield of HPMCP-RS-microparticles was calculated
based on all excipients in the formulations. The amount of
drug encapsulated in the microparticles was also determined.
The RS-microparticles and HPMCP-RS-microparticles were
dissolved in methanol and methanol/acetone (9:1; v/v), respectively, and the concentration of lansoprazole was analyzed
by HPLC. The amounts of lansoprazole encapsulated in the
microparticles in terms of encapsulation efficiency and drug
loading were calculated by Eq.(1) and Eq.(2), respectively.
Encapsulation Efficiency (%)=
amount of drug in microparti cles
amount of drug added initially * 100 % ...Eq.(1)
Encapsulation Efficiency (%)=
amount of drug in microparti cles
amount of drug added initially * 100 % ...Eq.(2)

dominated by polymer swelling (Case-II transport). A n value
between 0.43 and 0.85 indicates the drug release governed
by both mechanisms (anomalous transport). The t50% corresponded to the time when 50% drug was released and the
cumulative percentage of drug released at the end of 24 h was
further recorded.
Qt /Q0 = ktn……………………………………..Eq.(3)
VII. Differential Scanning Calorimetry (DSC) and FTIR
Spectroscopy Analysis
The thermal properties of lansoprazole, Eudragit®
RS-100, a physical mixture of lansoprazole and Eudragit®
RS-100, and lansoprazole-loaded RS-microparticles were
measured by DSC (LT-Modulate DSC 2920, TA Instrument
Ltd., USA). Samples (~2 mg) were heated to 250°C at a rate
of 10°C/min, and the thermograms were collected. These
four samples were further analyzed on a Fourier transform
infrared spectrophotometer (FT/IR-410, JASCO, Japan), and
the FTIR spectra were recorded. Each sample was mixed
with potassium bromide with a weight ratio of 1:50, and
compressed by an IR compressor at 3,000 psi. The potassium
bromide disk was measured by FTIR over the range of 4,000500 cm-1 with a resolution of 4 cm-1 for 100 scans.

RESULTS AND DISCUSSION
I. RS-Microparticles
The surface morphology of drug-loaded RS-microparticles was observed under scanning electron microscope (JEOL,
JSM-6300, Japan), and the micrograph is shown in Figure 1.
All of the microparticles had a spherical shape with a smooth
surface morphology irrespective of their formulations. The
effects of polymer concentration, drug concentration and

VI. InDrug
VitroLoading
Release (%)=
Study
amount of drug in microparti cles
100 %
Drug-loaded
microparticles
(200 mg) *were
suspended
total weight
of microparticles
in 5 mL carbonate buffer solution (pH 9.68) in a dialysis
bag, which
was placed
in a vial containing 60 mL of release
Drug Loading
(%)=
medium(24,25)
.
The
release
study was conducted
at 37°C, and
amount of drug in microparti
cles
*
100
%mL) were
the stirringtotal
speed
was
set
at
50
rpm.
Samples
(1
weight of microparticles
withdrawn at 0.5, 1, 2, 4, 6, 9, 12, 15, and 24 h, and the same
volume of fresh release medium was replaced. The sample
solutions were assayed by HPLC. The cumulative amount
of drug released at each sampling point was corrected for
the volume of the release medium. Each release profile was
fitted into Eq.(3), and the rate constant k and the exponent
constant n were elucidated(26). Qt/Q0 represents the cumulative percentage of drug released from the microparticles at
time t. A n value of 0.43 indicates the release governed by
Fickian diffusion while n value of 0.85 indicates the release

10 μm (500x)
Figure 1. The SEM micrograph of RS-microparticles.
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homogenization rate on particle size, yield, encapsulation
efficiency, and drug loading of RS-microparticles were
further discussed.

and resulted in high efficiency of drug encapsulation in
microparticles(27,28). The similar impact was observed from
RS-microparticles prepared under 2,000 rpm (Figure 2(b)).

II. Polymer Concentration Effect

III. Drug Concentration Effect

Figure 2(a) shows the influence of polymer concentration on particle size, yield, encapsulation efficiency, and drug
loading of RS-microparticles prepared at 4% drug concentration under 7,000 rpm. An increase in polymer concentration
from 4 to 8% did not affect the size, and the corresponding
value was around 3-4 mm. However, the particle size was
enlarged to 13.84 ± 0.31 mm when polymer concentration
was further increased to 16%. There was no significant
influence of polymer concentration on yield (64.87 ± 0.89 ~
68.00 ± 3.34%). However, there was a prominent increase in
encapsulation efficiency and drug loading of microparticles
as polymer concentration increased (p < 0.05). Increasing
the polymer concentrations produced more viscous internal
organic phase during microparticle preparation, which
prevented drug diffusion into the external aqueous phase

Figure 3(a) shows the influence of drug concentration on particle size, yield, encapsulation efficiency, and
drug loading of RS-microparticles prepared at 8% polymer
concentration under 7,000 rpm. There was no significant
effect of drug concentration on microparticle size in the range
of 0.8 to 8%. However, the yield and the drug encapsulation
efficiency were decreased by increasing the drug concentration. It was reported that lansoprazole is slightly soluble in
dichloromethane(29). When drug concentration was increased
from 0.8% to 8%, lansoprazole was no longer completely
dissolved in the internal organic phase during microparticle
preparation, which resulted in the poor yield and inferior
efficiency of drug encapsulation. The maximum drug loading
was obtained using microparticles prepared from a formulation of 4% drug concentration, and further increase in drug
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Figure 2. The influence of polymer concentration on particle size, yield, encapsulation efficiency, and drug loading of RS-microparticles prepared
at 4% drug concentration under (a) 7,000 rpm and (b) 2,000 rpm (n = 3).
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Figure 3. The influence of drug concentration on particle size, yield, encapsulation efficiency, and drug loading of RS-microparticles prepared at
8% polymer concentration under (a) 7,000 rpm and (b) 2,000 rpm (n = 3).
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concentration to 8% did not improve drug loading. The
similar result was observed from RS-microparticles prepared
under 2,000 rpm (Figure 3(b)).
IV. Homogenization Rate Effect
Figure 4 shows the influence of homogenization rate
on the particle size, yield, encapsulation efficiency, and drug
loading of RS-microparticles prepared from a formulation

(A)

100

RS-microparticle property

R8 7000-0.8

80

R8 2000-0.8

60

40

20

0
Size (um)

(B)

Yield (%)

EE (%)

DL (%)

V. In vitro Release Study

100

RS-microparticle property

R8 7000-4

80

containing 8% polymer concentration. The homogenization rate played an important role on the microparticle size
regardless of drug concentration (p < 0.05), and the sizes of
microparticles prepared under 7,000 and 2,000 rpm were ~4
mm and ~12 mm, respectively. Reduction of homogenization
rate from 7,000 rpm to 2,000 rpm exerted less shear force on
the droplet at the early stage, which resulted in the formation
of microparticles of larger size(30,31). There was no difference in yield, encapsulation efficiency, and drug loading of
microparticles prepared at 0.8% drug concentration under
variable homogenization rates (Figure 4(a)). However, the
influence of homogenization rate on microparticle performance became more significant when the drug concentration
was in the range of 4-8% (Figure 4(b) and 4(c)). Decrease
of homogenization rate from 7,000 rpm to 2,000 rpm had
a positive contribution on the encapsulation efficiency and
drug loading. This result indicated that smaller particle size of
microparticles prepared at 7,000 rpm did not favor the encapsulation of drug into microparticles. As mentioned before,
when the drug concentration was in the range of 4-8%, most
of drug was not completely dissolved in the internal organic
phase during microencapsulation process. The solid drug was
not feasible to be encapsulated in the smaller microparticles
prepared at 7,000 rpm.

Figure 5 shows the release of drug from six batches
of microparticles (R87000-4, R87000-8, R42000-8, R42000-4,
R82000-8 and R167000-4) with t50% in the range of 4-24 h,
where the t50% corresponded to the time at which 50% of drug
released. The cumulative percentage of drug released at the
end of 24 h was in the order of R42000-8 ~ R87000-4 > R87000-8
~ R42000-4 > R82000-8 > R167000-4, and the corresponding t50%
were 5.0, 4.6, 4.9, 6.8, 10.7, and 21.6 h. Increase in polymer
concentration not only prolonged t50% but also decreased the
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Figure 4. The influence of homogenization rate on particle size,
yield, encapsulation efficiency, and drug loading of RS-microparticles
prepared at 8% polymer concentration and various drug concentrations
(a) 0.8%, (b) 4.0% and (c) 8.0% (n = 3).
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Figure 5. The release of lansoprazole from six batches of RS-microparticles, R42000-8, R87000-4, R87000-8, R42000-4, R82000-8 and R167000-4
(n = 3). The dash line intersecting the x-axis indicates the t50%.
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Figure 6. The FTIR spectra of (a) lansoprazole, (b) Eudragit® RS-100, (c) physical mixture and (d) R82000-8 microparticles.

cumulative amount of drug released (e.g., R42000-8 vs R82000-8
and R87000-4 vs R167000-4). The release profiles were further
fitted by Eq.(3), and the associated k and n values were determined. The n values of R87000-4, R87000-8, R42000-8, R42000-4,
R82000-8 and R167000-4 were 0.45, 0.50, 0.59, 0.47, 0.43, and
0.58, respectively, with r > 0.98. According to the n values
proposed by Siepman and Peppas(32) for spherical particles,
it revealed that the release of drug from RS-microparticles
is governed by both Fickian diffusion and polymer swelling
mechanisms since all of the n values of RS-microparticles
were between 0.43 and 0.85.
VI. FTIR Determination and DSC Thermal Analysis
Figure 6 shows the FTIR spectra of lansoprazole,
Eudragit® RS-100, a physical mixture of both, and lansoprazole-loaded RS-microparticles (R82000-8). The peaks at
3235.63 and 1579.41 cm-1 were assigned to the N-H and
C=C bonds of lansoprazole, and the peak at 1731.76 cm-1 was
the C=O of Eudragit® RS-100. The indicating peaks corresponding to lansoprazole and Eudragit® RS-100 appeared
in the spectrum of the microparticles, which was similar to
that of their physical mixture. This observation indicated
no interaction between lansoprazole and Eudragit® RS-100.
Figure 7 shows their DSC thermograms. The endothermic

melting peak of lansoprazole appeared at 180.1°C followed
by an exothermic degradation peak, which also appeared in
the physical mixture. However, this peak disappeared from
the thermogram of microparticles, and a weak and broad peak
was observed instead. This result revealed that the encapsulated lansoprazole was present as an amorphous form in the
microparticles.
VII. HPMCP-RS-Microparticles
The R82000-8 microparticles were selected for enteric
coating due to acceptable t50% (10.7 hours) and better
drug loading (29.34 ± 2.48%), yield (60.62 ± 6.60%) and
encapsulation efficiency (58.75 ± 5.04%) among all of the
RS-microparticles. The particle size of R82000-8 microparticles after HPMCP coating was enlarged from 11.67 ± 1.31
mm to 28.84 ± 7.03 mm, and the yield was 81.94 ± 2.28%.
60.71 ± 1.19% of drug remained in enteric coated microparticles after treated in 0.1 N HCl for 1 h. HPMCP is well known
to play an important role on protecting acid-labile drug from
degradation in acidic condition. The lack of complete acidresistance ability of HPMCP coated microparticles could be
due to that some drug was extracted out of RS-microparticles
during enteric coating process and thus was immediately
degraded when directly contacted with the acidic medium in

444
Journal of Food and Drug Analysis, Vol. 20, No. 2, 2012
-17
-15

-10
-5
(a) Lansoprazole

Heat Flow Endo Down (mw)

0

5
10

(b) Eudragit® RS-100

15
20

(c) Physical mixture

25
30

(d) RS-Microparticles

35
40
24.59 40

60

80

100

120

140

160

180

200

220

246

Temperature (°C)

Figure 7. The DSC thermograms of (a) lansoprazole, (b) Eudragit® RS-100, (c) physical mixture and (d) R82000-8 microparticles.

the acid-resistant study. This might be overcome by adjusting
the pH of HPMCP coating solution to around 6.0-7.0 in order
to reduce the water solubility of lansoprazole during spray
drying process and to prevent lansoprazole leaking out of
RS-microparticles.

CONCLUSIONS
HPMCP-RS-microparticles with acid-resistance and
sustained-release properties were developed for lansoprazole. The solvent evaporation method followed by a spray
drying technique was applied to prepare the microparticles.
Three important variables including polymer concentration,
drug concentration and homogenization rate were optimized,
and R82000-8 microparticles with the high drug loading
(29.34 ± 2.48%), high encapsulation efficiency (58.75 ±
5.04%), high yield (60.62 ± 6.60%), and acceptable t50%
(10.7 h) were obtained. The in vitro release study demonstrated that release of the drug was governed by both Fickian
diffusion and polymer swelling mechanisms, where lansoprazole was physically encapsulated in RS-microparticles as an
amorphous form. The HPMCP enteric coated RS-microparticles (HPMCP-RS-MP) protected lansoprazole from degradation and improved its acid-resistance.
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